dr. patel on an analysis of olaparib and cediranib for ovarian cancer
Published 10 years ago • 416 plays • Length 2:12Download video MP4
Download video MP3
Similar videos
-
2:13
dr. patel on cediranib versus olaparib in recurrent platinum-sensitive ovarian cancer
-
1:38
dr. liu on cediranib/olaparib in recurrent ovarian cancer
-
0:53
dr. annunziata on olaparib and cediranib combination in ovarian cancer
-
0:55
a study of olaparib and cediranib in ovarian cancer
-
11:22
olaparib in ovarian cancer
-
1:25
olaparib in ovarian cancer
-
1:11
dr. ledermann on the additive effects of olaparib and bevacizumab in ovarian cancer
-
1:23
dr. robertson on olaparib for serous ovarian cancer
-
8:26
the impact of paola-1 on frontline treatment of ovarian cancer
-
1:54
dr. matulonis on toxicities with olaparib for patients with ovarian cancer
-
1:24
dr. ledermann on response to rucaparib in recurrent ovarian cancer
-
5:25
solo-1: frontline olaparib maintenance therapy in ovarian cancer
-
6:51
platinum sensitivity and parp inhibition in ovarian cancer
-
1:08
dr. essel on repeat use of parp inhibitors in ovarian cancer
-
1:20
dr. ledermann discusses olaparib in ovarian cancer
-
5:53
adverse-effect profiles of parp inhibitors in ovarian cancer
-
2:21
dr. rafii discusses clinical outcomes with olaparib in patients with ovarian cancer
-
2:09
dr. moore on the nova trial for ovarian cancer
-
1:25
dr. zakashansky on solo2 with maintenance olaparib in relapsed brca1/2 ovarian cancer